Pre-made Samalizumab benchmark antibody ( Whole mAb, anti-CD200 therapeutic antibody, Anti-MRC/MOX1/MOX2/OX-2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Samalizumab biosimilar, Whole mAb, Anti-CD200 Antibody: Anti-MRC/MOX1/MOX2/OX-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Samalizumab is a humanized monoclonal antibody designed for oncology indications.
| Products Name (INN Index) | Pre-Made Samalizumab biosimilar, Whole mAb, Anti-CD200 Antibody: Anti-MRC/MOX1/MOX2/OX-2 therapeutic antibody |
|---|---|
| INN Name | Samalizumab |
| Target | CD200 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2010 |
| Year Recommended | 2011 |
| Companies | Alexion Pharmaceuticals,The Leukemia & Lymphoma Society |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Acute myeloid leukaemia,Chronic lymphocytic leukaemia,Multiple myeloma,Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD200 |
| Package |
